

# **HIV-AIDS Associated Malignancies**

**Ronald Mitsuyasu, MD**

**Professor of Medicine, UCLA**

**Group Chairman,**

**AIDS Malignancy Consortium (AMC)**

**Support from National Cancer Institute**

**Office of HIV/AIDS Malignancies**

**Scot C. Remick, MD**  
**Chair, AMC International Resource**  
**Committee**

**Mary Babb Randolph Cancer Center**  
**West Virginia University**  
**Morgantown, WV, USA**



## **AIDS Malignancy Consortium**

- **Established in 1994 by NCI**
- **One of the few clinical trials groups in the world dedicated to malignancies in HIV**
- **Helps establish current standard of care for treatment of AIDS-KS, AIDS-NHL, HPV related diseases and non-AIDS defining cancers in the USA and explores novel, pathogenesis-based approaches to malignancies in HIV**
- **Recently underwent reorganization in 2006 with additional new focus on international trials**
- **Group consists of central leadership, Ops office, disease-specific working groups, resource committees, core labs and domestic and international sites**

## **Mission Statement**

**“The mission of the AMC is to investigate new treatment and prevention interventions of malignancies in people living with HIV both in the USA and internationally and to study the pathobiology of these tumors in the context of clinical trials.”**

# Goals and Objectives of the AMC

- Evaluate clinical interventions for the treatment and prevention of malignancies in people with HIV
- Investigate the biology of these malignancies in the context of clinical trials
- **Address issues of international importance in HIV associated malignancies**
- Interact and collaborate with other HIV clinical trials groups to address significant questions and to advance the field of research in HIV-associated malignancy
- Contribute specimens and clinical data to the ACSR

# **AMC International WG**

## **Specific Aims**

- **Assist with capacity building in developing nations for international HIV-related cancer research aligned with country's national AIDS research agendas and AMC goals**
- **Develop AMC-sponsored and other joint NIH-supported international collaborative studies with our partners emphasizing trials that:**
  - **Employ hypothesis-driven, scientifically sound, pragmatic, locally relevant and feasible therapies**
  - **Address important pathogenesis-based questions**
  - **Take advantage of unique scientific expertise in the AMC**
- **Capitalize on pragmatic clinical trial designs with laboratory correlative studies which can also serve as a conduit to obtain clinical samples for the NCI-sponsored AIDS and Cancer Specimen Resource (ACSR)**

# **IWG – *Guiding Principles***

- **Identify projects that are important and relevant to collaborating partners**
- **Need to facilitate acquisition of training and resources for proper conduct of clinical trials of malignancies in HIV (GCP, GLP, regulatory, data)**
- **Collaborative partners must be engaged in hypothesis generation and in all phases of protocol development**
- **Upon completion, demonstrable benefit to partners**
- **Project aligned with applicable standards of care**
- **Funding mechanisms / support must be identified**
- **Publications must properly cite partners role**
- **Bilateral commitment to international research and respect for cultural differences**

# Therapy in Resource Limited Settings

- **Distribution of cancers in differ in various parts of the world (e.g. high H/N, plasmablastic lymphoma in India, more conjunctival cancer in Africa)**
- **What treatments are available locally and which are reasonable to administer given local situation?**
- **What are the optimal treatments regimens which are easy and feasible to administer?**
- **What are the efficacy, tolerability and practical trade-offs which need to be considered?**
- **What prevention and risk reduction approaches can be effectively instituted?**

# Current AMC Collaborative Partners with Active Protocols

Country	Center(s)	PI	US Partner
Uganda	Makerere Univ. Uganda Cancer Inst.	J. Orem	Case / WVU
Kenya	Univ. Nairobi Kenyatta Natl. Hosp.	W. Mwanda	Case / WVU
Brazil	Federal Univ. of Bahia Emilio Ribas Institute	C. Brites T. Souza	Univ. Miami
India	YRG Cares	Kumarasamy	UCSF

# African Sites Participating in S002

<b>Site PI</b>	<b>AMC / US Partner</b>	<b>Institution</b>	<b>Country</b>
Adebamowo	U. Maryland	National Hospital	Abuja, Nigeria
Borok	U. Colorado	U. Zimbabwe	Harare, Zimbabwe
Busakhala	Indiana U.	Moi University	Eldoret, Kenya
Hosseinipour	U. North Carolina	Lighthouse Clinic	Lilongwe, Malawi
MacPhail	MSKCC	U. Witswatersrand	Johannesburg, S. Africa
Mossam	MSKCC	U. KwaZulu-Natal	Durban, S. Africa
Mwanda	West Virginia U.	U. Nairobi	Nairobi, Kenya
Ndom	UCSD	Yaounde U.	Yaounde, Cameroon
Novitsky	U. Miami	U. Cape Town	Cape Town, S. Africa
Orem	West Virginia U.	Makerere U.	Kampala, Uganda

# Current International Protocols

Protocol	Project	Site(s)	Comment
<b>AMC 049</b>	<b>Sunitinib in AIDS KS</b>	<b>Uganda, Kenya</b>	<b>On Hold</b>
<b>AMC 050</b>	<b>KSHV viral transcription</b>	<b>Brazil</b>	<b>Active</b>
<b>AMC 054</b>	<b>Quadrivalent HPV vaccine</b>	<b>India</b>	<b>Active</b>
<b>AMC 055</b>	<b>Indinavir endemic KS</b>	<b>Uganda</b>	<b>Active</b>
<b>AMC 060</b>	<b>HPV prevalence study</b>	<b>India</b>	<b>Active</b>
<b>S002</b>	<b>Cancer data registry</b>	<b>Multiple</b>	<b>Active</b>
<b>AMC Suppl</b>	<b>SCCA conjunctiva – HPV and EGFR 50 cases</b>	<b>Uganda, Kenya</b>	<b>Tissue study Completed</b>

# **Opportunities for Sites in Africa**

- **Engage in capacity building, training and technology transfer for clinical recognition, diagnosis and clinical therapeutic and prevention trials of common cancers in HIV**
- **Train pathologists and technicians in specific techniques and procedures needed for accurate diagnosis and characterization**
- **Establish infrastructure needed to participate in clinical trials and clinical research in collaboration with AMC**
- **Improve data capture methods to document epidemic of cancer in HIV**

# **AMC Clinical Trials Opportunities**

- **KS trials – ACTG 5263/AMC 066 and 5264/067**
  - **Tissue characterization of KS**
- **Lymphoma trials – AMC trials in development**
  - **Tissue characterization of lymphoma in HIV**
- **Cervical cancer trial – in development**
- **HPV trials - Cervical and anal screening**
  - **Early diagnosis and treatment for dysplasia (India)**
  - **Vaccine and other prevention approaches (India)**
- **Tumor identification and registration studies**
  - **Treatment and outcome measures for all HIV cancers**
- **Training new and junior investigators in AIDS oncology**

# **Collaborative Research in Africa**

## **Challenges (1)**

- **Peer review and Funding**
- **Tiers of regulatory and scientific review → years to develop a project and study must align with standards of care**
- **Ethical challenges and informed consent process**
- **Expanding laboratory and pathology support – correlative studies, routine histology, TMA and shipping of samples**

# **Collaborative Research in Africa**

## **Challenges (2)**

- **Cost of Treatment Regimens – Who will pay?**
- **Data Management and Data Sharing**
- **Data Safety Monitoring Plan(s) (*DSMP*)**
- **Monitoring and audit capacity – especially on site**
- **Specimen shipping – national regulations, logistics**
- **Coordination of scientific studies – the continent is getting crowded → numerous collaborative partners and agencies (even NIH effort)**

# **International AMC Collaboration Summary**

- **Feasible – growing problem in developing world**
- **Expand NIH scientific agenda**
  - **Epidemiological studies**
  - **Therapeutic pathogenesis-based and translational clinical trials**
  - **Tumor biology and basic virology investigation**
- **Support for pathogenesis-based correlative studies**
  - **Linkage to NCI – AIDS Cancer Specimen Resource (ACSR)**
  - **Develop on site laboratory capabilities ultimately**
- **Capacity Building, technology transfer and training opportunities**
- **Commitment to international research - sensitivity to local culture, epidemiology, scientific capability, and standards of care with collaborative partner**

# **ACTG 5293/AMC 066 and ACTG 5394/AMC 067**

- **Early Stage KS, naïve to ART**
  - HAART Alone vs HAART + oral etoposide
  - Composite endpoint of KS PFS and HIV progression and ART failure
- **Late Stage KS, naïve to ART**
  - All receive HAART
  - Randomized to also get either: oral etoposide, liposomal doxorubicin, or vincristine + bleomycin

NATIONAL  
CANCER  
INSTITUTE



AMC  
AIDS MALIGNANCY CONSORTIUM



National Institute of Allergy and Infectious Diseases  
National Institutes of Health



**CFAR**

CENTER FOR AIDS RESEARCH  
University of California Los Angeles



CARE

Clinical AIDS  
Research & Education

# Thank You

- For information on AMC clinical trials see:  
<http://pub.emmes.com/study/amc/public/index.htm>
- For information on NCI programs in HIV cancer see:  
<http://www.cancer.gov/cancertopics/types/AIDS>